Over the past few years, stocks from a variety of industries and sectors have dealt with unique challenges. While some companies are still dealing with the effects of slowing growth following the pandemic highs, look at the underlying business, not just the stock price, to see if the long-term buy proposition is intact. It is important to.
If you have $2,000 to invest in stocks right now, there are plenty of great companies begging to be acquired. Here are his two stocks you should consider adding to your buy basket right now. Both stocks have been significantly discounted in the market over the past 12 months.
1. Pfizer
pfizer (New York Stock Exchange: PFE) The company was forced to make significant adjustments as a company after the height of its success during the pandemic with its COVID-19 vaccine Comilnati and oral antiviral drug Paxrovid. It was inevitable that sales would plummet after demand for these products waned during the pandemic, but investor sentiment hasn’t been kind to the stock in recent months.
Last year, the stock price fell more than 30%. Pfizer stock is currently trading at an all-time high. Price relative to sales A multiple of approximately 2.6. Low valuations in and of themselves aren’t the only reason to buy the stock, but it’s definitely one to consider when considering one of the world’s largest pharmaceutical companies with a broad pharmaceutical portfolio and significant future growth potential. This will be the material. .
There is no denying that the slowdown in sales of products related to the novel coronavirus disease (COVID-19) has had a significant impact on Pfizer’s balance sheet. Still, Pfizer posted full-year sales of just under $59 billion in 2023. Furthermore, excluding products related to the new coronavirus infection, sales increased by 7% compared to the same period last year, a solid growth rate. For businesses at this stage of maturity.
Pfizer will be profitable in 2023, or net income based on generally accepted accounting principles (GAAP) totaled $2.1 billion, a significant decrease from a year ago, when 2022 net income was $31.3 billion. This is not simply due to a decline in product sales. Pfizer is investing heavily in future business growth, which is also impacting its earnings.
Last year, Pfizer completed the largest acquisition in its history when it acquired cancer drug specialist Seagen. This is a critical cog in Pfizer’s overall strategy to add $25 billion in annual revenue to its balance sheet by 2030 through external business development transactions.
The company had more products approved by the U.S. Food and Drug Administration last year than any other product and is working toward its goal of generating $70 billion to $84 billion in non-coronavirus revenue by 2030. I’m here. Management also stated in the 2023 earnings call: The addition of Seagen’s medicines and other portfolio products is expected to add at least eight new products to Pfizer’s lineup by 2030 with the potential to be blockbusters.
Meanwhile, investors have benefited from Pfizer’s lackluster stock performance, meaning its dividend yield has skyrocketed. As of this writing, the yield is approximately 6%. Pfizer has steadily raised its dividend over the years, posting a total growth rate of about 17% over the next five years alone.
The company is in the midst of a transition period, and investors who buy a piece of the company will likely feel the impact on stock performance in the near future. However, for long-term investors looking for consistent portfolio performance and passive dividend income, patience may be rewarded.
2. Teradoc
Teladoc (NYSE:TDOC) It has been sold off heavily by investors in recent months. As of this writing, the stock is down about 43% from a year ago and 34% since the beginning of 2024. I have been a loyal shareholder in this business for several years now and can attest to the following: The fact that it wasn’t an easy road. Although the negative tide in investor sentiment seems firmly against this stock at the moment, I maintain my position on this business, which still has great potential for long-term investors. I believe that it is hidden.
Investors appear to be stuck on some core issues that led to the sale. One is Teladoc’s notable slowdown in growth from the height of the pandemic. While growth has certainly slowed compared to pre-pandemic and early pandemic times, there is no denying that the pandemic has created a period of hyper-growth for businesses. If it weren’t for the pandemic, it might have been possible over a much longer period of time.
It was hoped that the trajectory would normalize once the pandemic spread. It is a mature business that continues to be a global leader in the telemedicine industry, a sector that is still steadily expanding as demand for high-quality virtual healthcare solutions continues around the world.
Another bottleneck for investors is continued unprofitability. Teladoc recorded nearly $14 billion worth of impairment charges in 2022, almost all of which were non-cash charges. Although the accounting loss is not very large, it is much better than the actual operating loss.
As of the fourth quarter of 2023, Teladoc’s net loss had narrowed to just about $29 million, compared to the $3 billion net loss it reported at the end of 2022. Additionally, adjusted earnings for the year totaled him $328 million. From 2022, it will increase by 33%.
It’s also worth pointing out that the company is raising cash at a healthy pace, with revenue trending upward. Teladoc’s 2023 revenue totaled $2.6 billion, an 8% increase from the previous year, and its full-year operating cash was $350 million.
Although total visits to Teladoc’s platform decreased slightly year over year, the company had 89.6 million integrated care members and 1.2 million chronic care enrollees at the end of 2023. These cohorts showed increases of 8% and 14%, respectively, from the end of 2022.
Investors probably shouldn’t expect pandemic-driven growth from this business, but that doesn’t mean the best days are behind them either. Teladoc’s growth story is far from over, and for forward-thinking investors, this battered stock could present an interesting buying opportunity at its current valuation.
Should you invest $1,000 in Pfizer right now?
Before purchasing Pfizer stock, consider the following:
of Motley Fool Stock Advisor Our analyst team has identified what they believe Best 10 stocks What investors can buy right now…and Pfizer wasn’t among them. These 10 stocks have the potential to generate impressive returns over the next few years.
stock advisor We provide investors with an easy-to-understand blueprint for success, including guidance on portfolio construction, regular updates from analysts, and two new stocks every month.of stock advisor Since 2002, the service has more than tripled S&P 500 returns*.
*Stock Advisor returns as of March 8, 2024
Rachel Warren We have a position at Teladoc Health. The Motley Fool has a position in and recommends Pfizer and Teladoc Health. The Motley Fool has Disclosure policy.
Do you have $2,000?Two Great Stocks for a Bull Market Originally published by The Motley Fool
